U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C27H44O3
Molecular Weight 416.6365
Optical Activity UNSPECIFIED
Defined Stereocenters 12 / 12
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TIGOGENIN

SMILES

[H][C@]12C[C@@]3([H])[C@]4([H])CC[C@@]5([H])C[C@@H](O)CC[C@]5(C)[C@@]4([H])CC[C@]3(C)[C@@]1([H])[C@H](C)[C@@]6(CC[C@@H](C)CO6)O2

InChI

InChIKey=GMBQZIIUCVWOCD-MFRNJXNGSA-N
InChI=1S/C27H44O3/c1-16-7-12-27(29-15-16)17(2)24-23(30-27)14-22-20-6-5-18-13-19(28)8-10-25(18,3)21(20)9-11-26(22,24)4/h16-24,28H,5-15H2,1-4H3/t16-,17+,18+,19+,20-,21+,22+,23+,24+,25+,26+,27-/m1/s1

HIDE SMILES / InChI
Tigogenin is a saponin and acts as a natural plant steroid which induces apoptosis in rheumatoid arthritis fibroblast-like synoviocytes. This action is associated with overexpression of COX-2 correlated with overproduction of endogenous PGE2. In addition, it was found that through the inhibition of PPAR gamma and via the p38 MAPK pathway tigogenin has the potential to prevent the development of osteoporosis and the related disorders.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P37231|||Q15179
Gene ID: 5468.0
Gene Symbol: PPARG
Target Organism: Homo sapiens (Human)
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
A new source for tigogenin.
1962 Apr
Tigogenin inhibits adipocytic differentiation and induces osteoblastic differentiation in mouse bone marrow stromal cells.
2007 May 30
Patents

Sample Use Guides

In Vivo Use Guide
Unknown
Route of Administration: Unknown
In Vitro Use Guide
Curator's Comment: Tigogenin was more effective than hecogenin in inducing apoptosis in human Rheumatoid arthritis (RA) fibroblast-like synoviocytes (FLS) which was caspase dependent but poly(ADP-ribose) polymerase independent and characterized by DNA fragmentation. It was demonstrated, that tigogenin-induced apoptosis through activation of p38 without affecting the JNK and ERK pathways. Indeed, pretreatment with a p38 inhibitor decreased saponin-induced apoptosis with a significant decrease in DNA fragmentation. Furthermore, the rate of apoptosis induced by tigogenin was associated with overexpression of COX-2 correlated with overproduction of endogenous PGE2.
Unknown
Name Type Language
TIGOGENIN
MI  
Common Name English
TIGOGENIN [MI]
Common Name English
(25R)-5.ALPHA.-SPIROSTAN-3.BETA.-OL
Systematic Name English
SPIROSTAN-3-OL, (3.BETA.,5.ALPHA.,25R)-
Systematic Name English
NSC-93754
Code English
TICOGENIN
Common Name English
Code System Code Type Description
ECHA (EC/EINECS)
201-041-9
Created by admin on Sat Dec 16 09:06:07 GMT 2023 , Edited by admin on Sat Dec 16 09:06:07 GMT 2023
PRIMARY
EPA CompTox
DTXSID40903920
Created by admin on Sat Dec 16 09:06:07 GMT 2023 , Edited by admin on Sat Dec 16 09:06:07 GMT 2023
PRIMARY
CHEBI
9595
Created by admin on Sat Dec 16 09:06:07 GMT 2023 , Edited by admin on Sat Dec 16 09:06:07 GMT 2023
PRIMARY
FDA UNII
4SMU15RR44
Created by admin on Sat Dec 16 09:06:07 GMT 2023 , Edited by admin on Sat Dec 16 09:06:07 GMT 2023
PRIMARY
PUBCHEM
99516
Created by admin on Sat Dec 16 09:06:07 GMT 2023 , Edited by admin on Sat Dec 16 09:06:07 GMT 2023
PRIMARY
NSC
93754
Created by admin on Sat Dec 16 09:06:07 GMT 2023 , Edited by admin on Sat Dec 16 09:06:07 GMT 2023
PRIMARY
MERCK INDEX
m10861
Created by admin on Sat Dec 16 09:06:07 GMT 2023 , Edited by admin on Sat Dec 16 09:06:07 GMT 2023
PRIMARY Merck Index
CAS
77-60-1
Created by admin on Sat Dec 16 09:06:07 GMT 2023 , Edited by admin on Sat Dec 16 09:06:07 GMT 2023
PRIMARY